Regen BioPharma

Regen BioPharma EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Regen BioPharma (RGBP) as of Nov 21, 2026 is -2.30. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -1.31 — a change of 76.50% (lower).

EV/OCF

-2.30

YoY

76.50%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Regen BioPharma is 2025 -2.30 . EV/OCF (Enterprise Value to Operating Cash Flow) of Regen BioPharma was 2024 -1.31 . It decreases by 76.50% lower compared to the previous year.

The Regen BioPharma EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-0.96 USD
Jan 1, 2019
-0.20 USD
Jan 1, 2020
4.86 USD
Jan 1, 2021
-2.61 USD
Jan 1, 2022
-2.16 USD
Jan 1, 2023
-4.17 USD
Jan 1, 2024
-1.31 USD
Jan 1, 2025
-2.30 USD
The Regen BioPharma EV/OCF history
YEAREV/OCFYoY
-2.30+76.50%
-1.31-68.73%
-4.17+92.83%
-2.16-16.93%
-2.61-153.60%
4.86-2,549.48%
-0.20-79.33%
-0.96+254.29%
-0.27+39.27%
-0.19+679.79%
-0.02-91.41%
-0.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Regen BioPharma Stock analysis

What does Regen BioPharma do? Regen Biopharma Inc develops regenerative medical applications and novel technologies through pre-clinical and Phase I/II clinical trials. The company focuses on immunology and immunotherapy, particularly mRNA and small molecule therapies for cancer and autoimmune disorders. Key products include HemaXellerate for blood disorders, DiffronC for gene silencing, dCellVax and tCellVax for cellular immunotherapy, Dura-CAR and KimerApt for cancer treatment, and BORIS for molecular targeting in cancer stem cells. These products target patients with blood disorders, cancer, and autoimmune conditions, with clinical trials advancing toward commercialization. The company generates revenue through the development and potential future commercialization of its therapeutic products. Investors and partners in the biotechnology sector fund its research and development activities, supporting the progression of clinical trials. Regen Biopharma's pipeline includes multiple product candidates in various stages of development, targeting high-need therapeutic areas with significant market potential. Regen Biopharma's focus on innovative therapies for cancer, autoimmune disorders, and blood conditions positions it to attract investment from biotech-focused venture capital firms and pharmaceutical companies seeking to acquire or partner on promising drug candidates. The company's clinical-stage products aim to address unmet medical needs, particularly in areas like aplastic anemia and cancer stem cell modulation, which are critical for patient outcomes. Regen BioPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Regen BioPharma stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Regen BioPharma is -2.30 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Regen BioPharma changed from -1.31 to -2.30, representing a 76.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Regen BioPharma since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Regen BioPharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Regen BioPharma

All Key Metrics — Regen BioPharma